Results 61 to 70 of about 25,289 (245)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.

, 2001
OBJECTIVE : The aim of this open multicentric study was to investigate the efficacy and safety of the addition of an angiotensin converting enzyme (ACE) inhibitor (benazepril, 10 mg/day) or a diuretic (hydrochlorothiazide, 12.5 mg/day) for 4 weeks in ...
Sadecky, L., Waeber, B., Aschwanden, R., Ferber, P.   +3 more
core   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives

, 2013
Background: A majority of hypertensives require treatment with >= 2 antihypertensive therapies to achieve blood pressure (BP) goals. Single-pill combinations (SPC) may improve convenience and adherence to therapy and reduce health care resource use ...
Sun, Ningling, Grosso, Amie, Zhu, Dingliang, Zhang, Ying, Yang, Kan, Wang, Ruonan, Gao, Pingjin   +6 more
core   +1 more source

Sacubitril/valsartan : um guia prático [PDF]

, 2019
© 2019 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction ...
Fonseca, Cândida, Franco, Fátima, Cardoso, José Silva, Ferreira, Jorge, Silva Cardoso, José, Morais, João, Brito, Dulce   +6 more
core   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Sacubitril/valsartan and isolated systolic hypertension in elderly patients: a prospective study

Известия высших учебных заведений. Поволжский регион: Медицинские науки
Background. The purpose of the research is to evaluate the antihypertensive efficacy of sacubitril/valsartan 200 mg/day compared with valsartan 160 mg/day in patients with grade 1–2 isolated systolic arterial hypertension (ISAH).
A.S. Ryazanov, M.V. Makarovskaya, N.A. Anisimov, L.V. Melnikova   +3 more
doaj   +1 more source

Application of PVP VA 64 and Poloxamer 188/407 in Solid Dispersion Technology for Improving Solubility of Valsartan

Pharmaceutical Sciences and Research
Valsartan, Biopharmaceutical Classification System (BCS) class II drug, exhibits pH-dependent solubility in the gastrointestinal tract, which increases at pH levels above 5.
Sulastari Cahyani, Teuku Nanda Saifullah Sulaiman, Marlyn Dian Laksitorini   +2 more
doaj   +1 more source

Higher persistence with valsartan compared with enalapril in daily practice

, 2008
Satu J Siiskonen1, Nancy S Breekveldt-Postma1, Gábor Vincze2, Zeba M Khan3, Joëlle A Erkens1, Ron MC Herings11PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis ...
Satu J Siiskonen, Nancy S Breekveldt-Postma, Gábor Vincze, et al, Zeba M Khan, Joëlle A Erkens   +5 more
core  

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source